Germany To Disclose Rx Pricing Discounts, Setting A Potential Benchmark For Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The Germany health ministry’s decision to continue the 16% rebate and price moratorium for another year was disappointing for industry, yet predictable. More distressing is the decision to publicly release the final prices – which will likely have a domino effect on reimbursement in other EU member states.
You may also be interested in...
German Parallel Importers Threaten Action Against Pharma Price Secrecy
Parallel traders of pharmaceuticals in Germany say that hiding the final price of products after negotiations between insurers and manufacturers could destroy their livelihood and is possibly illegal.
German Parliament Considers Lowering Mandatory Drug Rebate Level
The German Upper House has proposed reducing the obligatory rebate manufacturers of original drug products must give health insurers and closing a loophole in the law on generic drug discount contracts.
German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.